A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy,
safety, tolerability, PK, and pharmacodynamics of etigilimab in combination with nivolumab in
subjects with locally advanced or metastatic solid tumors. Subjects will be assigned to
receive etigilimab (every 2 weeks) in combination with nivolumab (240 mg every 2 weeks).